Common Stock, par value $0.0001 per share
- Symbol
- VVOS
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 7.01, 9.01 · 8-K
Vivos Therapeutics, Inc.
VVOSNASDAQEQUITYCurrent
Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. On August 20, 2026, Vivos Therapeutics, Inc. issued a press release announcing the opening of a new testing and treatment facility. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.…
Registered securities in this filing
Vivos Therapeutics, Inc. · 8-K · Filed 2026-08-21
Disclosure sections
Item 7.01Item 7.01 - Regulation FD Disclosure
Item
7.01. Regulation FD Disclosure.
On
August 20, 2026, Vivos Therapeutics, Inc. issued a press release announcing the opening of a new testing and treatment facility.
A
copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The
information furnished pursuant to Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed”
for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section,
and shall not be deemed incorporated by reference into any filing under the Securities Act, or the Exchange Act, as amended, except as
expressly set forth by specific reference in such filing.
Filed exhibits (1)
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Vivos Therapeutics Opens New Sleep Testing and Treatment Facility in Nevada to Meet Rapidly Growing Patient Demand for Sleep Apnea Testing and Treatment New Location Expected to More Than Double Annual Revenue Production Capacity to Over $10 Million Official Grand Opening Slated for August 27 in Henderson, Nevada With Prominent Industry Opinion Leaders, Sleep Physicians, Dentists Among Scheduled Attendees LITTLETON, Colo., August 20, 2026 - Vivos Therapeutics, Inc. (“Vivos” or “the Company”) (Nasdaq: VVOS), a leading medical device and healthcare services company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from obstructive sleep apnea (“OSA”) and other sleep disorders, today announced the official Grand Opening of its latest state-of-the-art diagnostic, testing, and treatment location in Henderson, Nevada. The Company expects this new full-service center will more than double the annual production capacity in Henderson to more than $10 million. At full capacity, the facility is expected to employ up to 30 personnel, including board certified medical doctors, special…
Open exhibit ↗